Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2786-2791

  Conter, V ^a   Schrappe, M ^a   Arico M ^a   Reiter, A ^a   Rizzari, C ^a   Dordelmann M ^a   Valsecchi, M G ^a   Zimmermann, M ^a   Ludwig, W D ^a   Basso, G ^a   Masera, G ^a   Riehm, H ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERWINIA; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNOPHENOTYPING; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; STEROID THERAPY; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 17144452253     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2786     Document Type: Article

References (28)

1. Paolucci G, Masera G, Vecchi V, et al: Treating childhood acute lymphoblastic leukemia (ALL): Summary often years' experience in Italy. Med Pediatr Oncol 17:83-91, 1989
2. Riehm H, Gadner H, Henze G, et al: Acute lymphoblastic leukemia: Treatment results in three BFM studies (1970-1981), in Murphy SB, Gilbert JR (eds): Leukemia Research: Advances in Cell Biology and Treatment. New York, NY, Elsevier, 1983, pp 251-260
3. Riehm H, Gadner H, Henze G, et al: Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Bluttransf 33:439-450, 1990
4. Rivera GK, Pinkel D, Simone JV, et al: Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children Research Hospital. N Engl J Med 329:1289-1295, 1993
5. Crist WM, Shuster JJ, Look T, et al: Current results of studies of immunophenotype-, age-, and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Leukemia 6:162-166, 1992
6. Ludwig W-D, Teichmann JV, Sperling C, et al: Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia in children: Experiences of the ALL-BFM 83 and 86 studies. Klin Paediatr 202:243-252, 1990
7. Aricò M, Basso G, Mandelli F, et al: Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 75:1684-1693, 1995
8. Reiter A, Schrappe M, Ludwig W-D, et al: Chemotherapy in 998 unselected childhood Acute Lymphoblastic Leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
9. Clavell LA, Gelber RD, Cohen HJ, et al: Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
10. Riehm H, Reiter A, Schrappe M, et al: Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Paediatr 199:151-160, 1987
11. Schrappe M, Reiter A, Sauter S, et al: Concepts and interim analysis of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: The significance of initial therapy response in blood and bone marrow. Klin Paediatr 206:208-221, 1994
12. Conter V, Rizzari C, Aricò M, et al: Preliminary results of the AIEOP'91 study for childhood acute lymphoblastic leukemia (ALL). Med Pediatr Oncol 25:283, 1995 (abstr)
13. Bennett JM, Catovsky D, Daniel M-T, et al: Proposals for the classification of the acute leukemias. French-American-British cooperative group. Br J Haematol 33:451-458, 1976
14. Basso G, Rondelli R, Putti MC, et al: Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: The experience of the AIEOP cooperative study. Recent Results Cancer Res 131:297-307, 1993
15. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, pp 163-188
16. Raimondi SC: Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 81:2237-2251, 1993
17. Romana SP, Poirel H, Leconiat M, et al: High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86:4263-4269, 1995
18. Trueworthy R, Shuster J, Look T, et al: Ploidy of lymphoblasts is the strongest predictor of treatrrtent outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 10:606-613, 1992
19. Pui CH, Behm FG, Crist WM: Clinical and biologic relevance of immunologic marker study in childhood acute lymphoblastic leukemia. Blood 82:343-362, 1993
20. Pui CH, Behm F, Singh B, et al: Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 75:174-179, 1990
21. Shuster JJ, Falletta J, Pullen DJ, et al: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 75:166-173, 1988
22. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Prevention of CNS disease in intermediate risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group report. J Clin Oncol 11:520-526, 1993
23. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
24. Conter V, Aricè M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with BFM-based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995
25. Janka-Schaub GE, Gobel U, Graubner U, et al: Improved diagnosis for childhood acute lymphoblastic leukemia with very high white blood cell count (> 100/nl with rotation of non-cross-resistant drug combinations. Hematol Blood Transfus 33:489-493, 1990
26. Creutzig U, Ritter J, Zimmermann M, et al: Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 11:279-286, 1993
27. Henze G, Fengler R, Hartmann R, et al: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166-1172, 1991
28. Otten J, Suciu S, Lutz P, et al: The importance of L-asparaginase (A'ASE) in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase in trial showing greater efficiency of Escherichia coli (E coli) as compared to Erwinia (ERW) A'ASE. Blood 88:669, 1996 (suppl 1, abstr 2663)